Zobrazeno 1 - 10
of 132
pro vyhledávání: '"Sathibalan Ponniah"'
Autor:
San Jiun Chai, Sammuel Chee Yong Fong, Chai Phei Gan, Kin Choo Pua, Paul Vey Hong Lim, Shin Hin Lau, Rosnah Binti Zain, Thomas Abraham, Siti Mazlipah Ismail, Zainal Ariff Abdul Rahman, Sathibalan Ponniah, Vyomesh Patel, Sok Ching Cheong, Kue Peng Lim
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 1, Pp 167-178 (2019)
Peptide vaccines derived from tumour-associated antigens have been used as an immunotherapeutic approach to induce specific cytotoxic immune response against tumour. We previously identified that MAGED4B and FJX1 proteins are overexpressed in HNSCC p
Externí odkaz:
https://doaj.org/article/ba11ad8f5d45434c845f6d791e87ae5c
Autor:
San Jiun Chai, Yoke Yeow Yap, Yoke Ching Foo, Lee Fah Yap, Sathibalan Ponniah, Soo Hwang Teo, Sok Ching Cheong, Vyomesh Patel, Kue Peng Lim
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0130464 (2015)
Nasopharyngeal carcinoma (NPC) is highly prevalent in South East Asia and China. The poor outcome is due to late presentation, recurrence, distant metastasis and limited therapeutic options. For improved treatment outcome, immunotherapeutic approache
Externí odkaz:
https://doaj.org/article/1b49e9fe94a34fc1812e261c02303d23
Autor:
Kue Peng Lim, Nicole Ai Leng Chun, Siti Mazlipah Ismail, Mannil Thomas Abraham, Mohd Nury Yusoff, Rosnah Binti Zain, Wei Cheong Ngeow, Sathibalan Ponniah, Sok Ching Cheong
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e103975 (2014)
Regulatory T cells (Tregs), a subset of CD4+ T cells plays a pivotal role in regulating the immune system. An increase in Treg numbers enables cancer progression by dampening the immune system and allowing tumor cells to evade immune detection and de
Externí odkaz:
https://doaj.org/article/6ddb7292674a4a269ca2299e8f4ffb65
Autor:
Sathibalan Ponniah, Tommy A. Brown, Diane F. Hale, Constantin N. Baxevanis, N. F. Pistamaltzian, John W. Myers, Kaitlin M. Peace, Eleftheria A. Anastasopoulou, Doreen O. Jackson, Jennifer K. Litton, James L. Murray, Michael Papamichail, Nathan M. Shumway, James T. Symanowski, George E. Peoples, Alexandros Ardavanis, Elizabeth A. Mittendorf, Sonia A. Perez, Timothy J. Vreeland, Julia M. Greene, G. Travis Clifton
Publikováno v:
Breast Cancer Research and Treatment
Purpose AE37 and GP2 are HER2 derived peptide vaccines. AE37 primarily elicits a CD4+ response while GP2 elicits a CD8+ response against the HER2 antigen. These peptides were tested in a large randomized trial to assess their ability to prevent recur
Autor:
Diane F. Hale, Sathibalan Ponniah, Nathan M. Shumway, Michael Papamichail, Sonia A. Perez, Jennifer K. Litton, George E. Peoples, Alexandros Ardavanis, James L. Murray, Elizabeth A. Mittendorf, Constantin N. Baxevanis
Publikováno v:
Oncotarget
// Elizabeth A. Mittendorf 1,* , Alexandros Ardavanis 2 , Jennifer K. Litton 3 , Nathan M. Shumway 4 , Diane F. Hale 5 , James L. Murray 3 , Sonia A. Perez 2 , Sathibalan Ponniah 6 , Constantin N. Baxevanis 2 , Michael Papamichail 2 and George E. Peo
Autor:
Eleftheria A. Anastasopoulou, Alexandros Ardavanis, N. F. Pistamaltzian, George E. Peoples, Constantin N. Baxevanis, Diane F. Hale, Nathan M. Shumway, James L. Murray, Michael Papamichail, Sonia A. Perez, James T. Symanowski, Jennifer K. Litton, Sathibalan Ponniah, E. von Hofe, Elizabeth A. Mittendorf
Publikováno v:
Annals of Oncology. 27:1241-1248
Background AE37 is the Ii-Key hybrid of the MHC class II peptide, AE36 (HER2 aa:776–790). Phase I studies showed AE37 administered with granulocyte macrophage colony-stimulating factor (GM-CSF) to be safe and highly immunogenic. A prospective, rand
Autor:
JP Holmes, George E. Peoples, Erika J Schneble, Guy T. Clifton, Sathibalan Ponniah, D. A. Van Echo, Elizabeth A. Mittendorf
Publikováno v:
Annals of Oncology. 25:1735-1742
Background: E75 (nelipepimut-S) is a human leukocyte antigen (HLA)-A2/A3-restricted immunogenic peptide derived from the HER2 protein. We have conducted phase I/II clinical trials vaccinating breast cancer patients with nelipepimut-S and granulocyte
Autor:
G. Travis Clifton, Victor Gall, Jennifer K. Litton, Gheath Alatrash, Sathibalan Ponniah, Karen Arrington, Elizabeth A. Mittendorf, Nuhad K. Ibrahim, George E. Peoples
Publikováno v:
Annals of surgical oncology. 24(8)
CD8+ T cell-eliciting vaccines are being investigated in breast cancer patients. Preclinical data showed that trastuzumab increases the susceptibility of tumor cells to lysis by vaccine-generated CD8+ T cells, suggesting potential benefit of a combin
Autor:
George E. Peoples, Alfred F. Trappey, BS John, Guy T. Clifton, Nathan M. Shumway, Erika J Schneble, Diane F. Hale, Sathibalan Ponniah, Michael Papamichail, Sonia A. Perez, EA Mittendorf, Timothy J. Vreeland
Publikováno v:
Cancer Research. 73:P2-14
Background: HER2 over-expression is associated with more aggressive malignant disease. The introduction of trastuzumab and other HER2-directed therapies, however, has led to improved prognosis for patients (pts) with HER2 over-expressing (OE) tumors.
Autor:
Timothy J. Vreeland, Erika J Schneble, George E. Peoples, Sathibalan Ponniah, Alfred F. Trappey, Alan K. Sears, EA Mittendorf, Guy T. Clifton, Nathan M. Shumway, John S. Berry, Diane F. Hale
Publikováno v:
Cancer Research. 73:P4-13
BACKGROUND: HER2 is a commonly expressed tumor-associated antigen in breast (BrCa) and ovarian cancer (OvCa) and, therefore, an attractive target for immunotherapy. We have investigated HER2-derived peptides as vaccines mixed with GM-CSF to include G